Why Is Penny Stock Apollomics Trading Higher On Tuesday?
Portfolio Pulse from Vandana Singh
Apollomics Inc. (NASDAQ: APLM) saw a significant stock surge on Tuesday following the announcement of promising preliminary clinical data from its Phase 2 SPARTA trial of vebreltinib. The trial showed a 43% objective response rate in patients with non-CNS MET fusion solid tumors, including one complete response and five partial responses. The company is now evaluating further development opportunities for vebreltinib.
August 13, 2024 | 3:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apollomics Inc. (NASDAQ: APLM) stock surged 15.6% after the company announced promising preliminary clinical data from its Phase 2 SPARTA trial of vebreltinib. The trial showed a 43% objective response rate in patients with non-CNS MET fusion solid tumors, including one complete response and five partial responses. The company is now evaluating further development opportunities for vebreltinib.
The positive clinical trial results for vebreltinib, showing a high objective response rate, are likely to boost investor confidence and drive the stock price higher in the short term. The company's plans to further develop the drug add to the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100